Compare CACI & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CACI | MRNA |
|---|---|---|
| Founded | 1962 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 11.5B |
| IPO Year | 1979 | 2018 |
| Metric | CACI | MRNA |
|---|---|---|
| Price | $640.34 | $45.17 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 13 |
| Target Price | ★ $648.18 | $32.75 |
| AVG Volume (30 Days) | 327.9K | ★ 14.2M |
| Earning Date | 01-21-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.49 | N/A |
| EPS | ★ 23.34 | N/A |
| Revenue | ★ $8,978,846,000.00 | $2,232,000,000.00 |
| Revenue This Year | $11.18 | N/A |
| Revenue Next Year | $7.36 | $3.18 |
| P/E Ratio | $27.55 | ★ N/A |
| Revenue Growth | ★ 10.41 | N/A |
| 52 Week Low | $318.60 | $22.28 |
| 52 Week High | $683.50 | $55.20 |
| Indicator | CACI | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 65.50 | 63.48 |
| Support Level | $623.69 | $39.21 |
| Resistance Level | $683.50 | $51.18 |
| Average True Range (ATR) | 24.18 | 3.33 |
| MACD | 4.26 | 0.46 |
| Stochastic Oscillator | 61.13 | 56.37 |
CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.